Background: There is a growing interest in periconceptional iron supplementation in developing countries by researchers and policy makers; however, there are no randomized controlled trials that examine the effectiveness of this strategy in decreasing anemia during pregnancy. Objective: The aim was to determine whether periconceptional iron supplementation reduces anemia during pregnancy. Design: A randomized, double-blind, controlled trial was conducted in rural Bangladesh. Married, nulliparous women were randomly assigned to receive daily iron and folic acid (IFA; 60 mg ferrous fumarate and 400 lg folic acid) (n = 134) or folic acid (FA; 400 lg) (n = 138) in the form of a powdered supplement added to food. Women were followed until pregnancy or the end of 9 mo. Primary outcomes included hemoglobin, plasma ferritin, and plasma transferrin receptor concentrations. Results: Among 88 pregnant women, periconceptional IFA in comparison with FA did not affect anemia or iron status at 15 wk gestation. However, each 1% increase in adherence was associated with a 10-g/L increase in change in hemoglobin from baseline (P = 0.03), and those who initiated supplementation at a mean (6SD) time of 72.9 6 57.8 d before conception showed a 7.3-g/L increase in change in hemoglobin from baseline compared with those who initiated supplementation at 26.3 6 12.3 d after conception (P = 0.01). Among 146 nonpregnant women, IFA decreased anemia (odds ratio: 0.19; 95% CI: 0.04, 0.95) and improved iron stores (P = 0.001) more than did FA. Conclusion: Good adherence and initiation of supplementation before conception are needed to reduce anemia during early pregnancy. This trial was registered at www.clinicaltrials.gov as NCT00953134.
INTRODUCTION
The global figures for the prevalence of anemia among nonpregnant and pregnant women are 35% and 51%, respectively (1) . The major cause of nutritional anemia is iron deficiency (2) . Iron intervention programs during pregnancy have traditionally been initiated between 10 and 15 wk of gestation when a pregnant woman attends her first prenatal visit (3, 4) . However, '50% of women in developing world settings enter pregnancy with inadequate iron stores to meet pregnancy requirements (3, 5) . Recent evidence suggests that anemia before conception may be associated with an increased risk of low-birth-weight deliveries and fetal growth restriction (6) . Maternal iron deficiency in the first trimester of pregnancy has been associated with significant decrements in infant size at birth (7, 8) , and well-designed randomized controlled trials of iron supplementation starting early in pregnancy have shown significant reductions in the frequency of low-birth-weight infants (7, 9, 10) .
Periconceptional iron and folic acid (IFA) supplementation has been suggested as a complementary strategy to traditional iron supplementation that commences after pregnancy is confirmed and/or a woman knows she is pregnant (11, 12) . The rationale for IFA supplementation in nonpregnant women in developing countries is to treat preexisting anemia, increase body iron stores, and reduce the risk of neural tube defects. Iron supplementation programs during pregnancy have shown limited effectiveness because of low adherence, inefficient health care service delivery, and high rates of preexisting anemia, infection, and adolescent childbearing (3, 13, 14) . In young infants, poor adherence to standard iron drops led to the development of a powdered micronutrient supplement as an alternative delivery method. Powdered micronutrient supplements are a home-fortification method whereby micronutrients are added to foods prepared in the home. The use of a powdered micronutrient supplement among adolescent and adult women has not been well studied. A single study found that a powdered micronutrient supplement was as efficacious as a tablet supplement in eliciting a hemoglobin response among pregnant women in Bangladesh (15) . Further studies are needed to examine alternative methods of supplementation among other high-risk age groups.
In Bangladesh, anemia affects 43% of adolescents, 45% of nonpregnant women, and 49% of pregnant women (16) . In 2007 the National Strategy for Anemia Prevention and Control in Bangladesh included adolescents and newly married women as important target groups for IFA supplementation programs (17) . However, no study to date has examined the effect of periconceptional IFA supplementation on iron status during pregnancy in Bangladesh. The primary aim of our study was to examine the effect of daily periconceptional IFA compared with folic acid (FA) in a powdered supplement on anemia, hemoglobin concentrations, and other iron indicators during pregnancy. The periconceptional period was defined as the period before the ascertainment of a pregnancy during the study period. Outcomes were also measured for women who did not become pregnant during the study period.
SUBJECTS AND METHODS

Study setting and design
The study site was a 22-square-kilometer area in Kaliganj, 1 of the 5 administrative divisions in the Gazipur district in central Bangladesh. This rural area has a high population density, relies primarily on agricultural labor, and is a predominantly Muslim population. We conducted a randomized controlled trial from March 2007 to the end of February 2008. Participants were randomly assigned to receive IFA or FA and then followed up monthly for 9 mo or until they became pregnant. The primary outcome was hemoglobin concentration among women who became pregnant (IFA compared with FA). On the basis of our sample size calculations, we estimated that 30 pregnancies per group would be an adequate sample size to detect a clinically and statistically significant difference of 8 g/L in hemoglobin concentration between experimental and control groups (on the basis of 80% power and an SD of 11 g/L) (18) . On the basis of a pilot study, we assumed that 20% of women would become pregnant; thus, we aimed to recruit 152 women per group. To identify eligible women, field interviewers made house-to-house visits starting with households located nearest to the medical clinic where blood samples would be collected and moved outward from this location in a circular fashion. Women were ineligible if they met at least one of the following criteria: not married, had previously given birth, age 40 y old, not a permanent household member (living in household ,6 mo), not living in same household as their husband, using an implant form of birth control, previous surgery to prevent pregnancy, had used iron supplements within the previous 3 mo, were known to be pregnant at enrollment, or were identified as severely anemic at baseline (hemoglobin concentration of ,70 g/L) (1). Severely anemic women (n = 1) were excluded from the study and provided with iron supplements. At recruitment, women who were otherwise deemed eligible but had not menstruated for .45 d were administered a urine pregnancy test. Only women with a negative urine pregnancy test were included in the study.
Intervention
Women were randomly assigned to receive daily iron (60 mg as ferrous fumarate) and FA (400 lg) or FA alone (400 lg). The iron dose corresponds to recommendations for areas in which the prevalence of anemia is .40% (19) . The FA dose is based on the amount of synthetic FA recommended for women who plan a pregnancy (or are capable of becoming pregnant) for prevention of a neural tube defect (20) . FA was used as the control because the protective effect of folate against the development of neural tube defects, specifically anencephaly and spina bifida, is well established (21, 22) . In keeping with standard care in Bangladesh, once a pregnancy was confirmed, women were removed from the study and advised to take IFA supplements (17) . Nutrients were delivered in a powdered form in individual sachets. Sachets were identical in appearance, except for a small embossed letter on the back of the sachet to identify the treatment group ("A" or "B"). The use of these sachets, which contained powdered micronutrients, is a home-fortification strategy that allows micronutrients to be added to semisolid foods for consumption (Sprinkles; Ped-Med Ltd, Toronto, Canada). Powdered micronutrient supplements have successfully been evaluated for efficacy in infants and young children and for acceptability and safety in diverse settings (23, 24) . Each woman was given 35 sachets at enrollment and at each monitoring visit (30 sachets for a 1-mo daily supply and 5 extra sachets). Participants were instructed to pour the entire contents of the package into any semiliquid food after the food had been cooked and at a temperature acceptable to eat and then to mix it into the food. Participants were told to use one full package per day at any mealtime.
Data Collection
Study participants were administered a standardized baseline interview on socioeconomic and reproductive health factors. Anthropometric measurements included weight and height. Field interviewers visited participants once a month to replenish supplies of sachets, to count the number of empty sachet packages, to monitor side effects, and to encourage women to consume the contents of the sachets. For each participant, adherence was calculated as percentage of the total eligible doses consumed during the study period. During monthly visits, participants were asked if they had menstruated in the past 45 d. After 2 missed menstruations, a urine-based human gonadotropin pregnancy test was administered. Venous blood samples were collected at baseline and after a pregnancy was ascertained or after 9 mo among nonpregnant women. Interviewers read an approved assent form to the study participants and obtained oral and thumbprint consent. Ethical approval was obtained from the Medical Research Council in Bangladesh and the Hospital for Sick Children in Toronto, Canada.
Laboratory Analysis
Hemoglobin was assessed using a hemoglobinometer (HemoCue, Angelholm, Sweden). Hemocue machines were checked daily against a standard. Venous blood was centrifuged at 1500 · g for 10 min, and plasma was separated from cells. Aliquots of plasma were stored at 220°C and shipped in a frozen state on dry ice to the International Centre for Diarrheal Disease Research, Bangladesh (ICDDR,B) for plasma ferritin and transferrin receptor (TfR) analyses and to the Hospital for Sick Children (Toronto, Canada) for plasma folate analyses. Aliquots of plasma for folate analyses included sodium ascorbate (1%, wt:vol) to prevent the oxidation of folate. Plasma ferritin was measured by using an enzyme-linked immunosorbent assay method with a commercial kit (Roche Diagnostics, Indianapolis, IN) with an interassay CV of ,4.0%. Plasma TfR was measured by using an enzyme-linked immunosorbent assay method with a commercial kit (BioVendor, Modrice, Czech Republic) with an interassay CV of ,3.3%. C-reactive protein was measured at baseline by using a latex agglutination method and the automated method on the Roche Integra 400 (Roche Diagnostics) with an analytic goal of 610%. Plasma folate concentrations were measured by using a microbiologic assay that uses the test organism Lactobacillus rhamnosus (ATCC 7649; American Type Tissue Culture Collection, Manassas, VA) as described by Molloy and Scott (25) . The accuracy and reproducibility of these assays were assessed by using a wholeblood control standard with a certified value (29.5 nmol/L) (Whole Blood 95/528; National Institute of Biological Standards and Control, Hertfordshire, United Kingdom). Analysis of the whole-blood standard in our laboratory yielded a folate content of 31.0 6 2.4 nmol/L with an interassay CV ,9.4%.
Statistical analysis
An intent-to-treat analysis was performed. Analyses were conducted separately for pregnant women (IFA compared with FA) and nonpregnant women (IFA compared with FA). The main outcomes were anemia and changes in hemoglobin, plasma ferritin, and plasma TfR concentrations from baseline. Anemia was defined as hemoglobin ,120 g/L among nonpregnant women and hemoglobin ,110 g/L among pregnant women (26, 27) . Plasma ferritin concentrations were log-transformed. As a secondary analysis, change in plasma folate concentrations from baseline were examined in both treatment groups. Plasma folate concentrations were also examined by using linear regression analysis with the independent variable adherence to examine the accuracy of self-reported intake of supplements. Univariate analyses of hematologic indexes were performed by using t tests for continuous variables and chi-square tests for categorical variables. Multivariate analyses were performed by using linear regression models for continuous response variables and logistic regression for the binary response variable for anemia.
Multivariate analyses for pregnant women were adjusted for treatment group, literacy, adherence, gestational age, and timing of supplementation. Gestational age was the number of days since last menstruation reported by women who were identified as pregnant after 2 missed menstruations and a positive urine pregnancy test. Timing of supplementation is the number of days between commencement of supplementation and conception (days of last menses minus first day of supplementation). Timing of supplementation was examined as a continuous variable and as a categorical variable by categorizing pregnant women into those who initiated supplementation before and after conception, respectively. Multivariate analyses for nonpregnant women were adjusted for literacy and adherence. A 2-sided P value of 0.05 indicated statistical significance. Statistical analyses were conducted by using SAS (version 9.1; SAS Institute, Cary, NC).
RESULTS
Of the 15,357 women who were initially assessed for inclusion, 303 were eligible to participate (Figure 1) . A total of 15,085 women were excluded because they did not meet inclusion criteria [eg, not married (n = 7407)], had already given birth (n = 6387), no longer married (n = 26), age . 40 y old (n = 976), not living with their husband (n = 158), not a permanent household member (n = 47), using a permanent form of contraception (n = 19), use of an iron supplement in the past 3 mo (n = 2), and severely anemic (n = 1). A small number refused to participate (n = 25) or were unreachable (n = 6). A total of 272 women were randomized to supplement groups, giving an acceptance rate of 89.8%. Baseline characteristics have been described elsewhere (28) . No differences existed between groups, except in literacy (see Table S1 under "Supplemental data" in the online issue). Women who were randomly assigned to the IFA group had a higher literacy rate (able to read and write a letter) than those in the FA group (P = 0.02). A separate comparison of baseline and follow-up measures for pregnant and nonpregnant women showed no significant differences by supplement group, except for a significantly higher proportion of literate pregnant women in the IFA group ( Table 1) . Literacy was adjusted for in all multivariate analyses. There were no statistically significant differences in baseline characteristics or in biochemical indexes for iron and folate between women who completed the study and those lost to follow-up (data not shown).
During the 9 mo trial, 88 pregnancies were confirmed by urine testing: 43 in the IFA group and 45 in the FA group. The median (range: 0-100) time since last menstruation was 15 wk (6-21 wk) and was not statistically different between the IFA and FA groups (P = 0.69). There was an unexpectedly long delay between recruitment and the first monthly follow-up visit. Due to this delay, some women who initially reported that they were menstruating at recruitment (and thus were eligible for the study) had stopped menstruating (had become pregnant) by the first monthly visit. For this reason, a small number of women (n = 31) had an unidentified pregnancy between recruitment and the first monthly follow-up visit. These 31 women received supplements for a mean (6SD) time of 26.3 6 12.3 d after conception. The majority of women (n = 57) started supplementation before conception (72.9 657.8 d before estimated conception). The mean (6SD) number of days between recruitment and the first monthly follow-up visit was 40.3 6 9.9 d for 229 participants. Five participants were not reached until the next visit, '1 mo later. The number of days between initiation of supplementation and conception did not differ by supplement group (P = 0.27). The median number of days from when supplementation was commenced and conception occurred, as indicated by last menstruation was 25.5 d and ranged (first-third quartiles) from 216.5 to 82.5 d.
The results of multivariate analyses showed that daily periconceptional IFA supplementation compared with FA supplementation did not reduce anemia or improve iron status among pregnant women ( Table 2) . Among pregnant women, overall percentage adherence and timing of supplementation in relation to conception were found to be significantly associated with change in hemoglobin concentration from baseline ( Figure 2) . Each 1% increase in percentage adherence was associated with a 10-g/L improvement in change in hemoglobin from baseline (P = 0.03). Women who initiated supplementation before conception showed a 7.3 g/L greater change in maternal hemoglobin from baseline compared with those who initiated supplementation after conception (P = 0.01). Timing of supplementation as a continuous variable was not significantly associated with change in hemoglobin (P = 0.37).
Among nonpregnant women, daily periconceptional IFA supplementation for 9 mo compared with FA supplementation significantly improved iron stores (P = 0.001) ( Table 3 ). There were no significant differences between IFA and FA groups in changes in hemoglobin from baseline. However, with the use of the cutoff of a hemoglobin concentration 120 g/L to define anemia among nonpregnant women, IFA supplementation significantly reduced anemia compared with FA supplementation (odds ratio: 0.19; 95% CI: 0.04, 0.95). There were no significant differences between IFA and FA groups in changes in plasma TfR concentrations from baseline.
At baseline, the median (first-third quartile) plasma folate concentration was 15.9 nmol/L (12.1-20.5 nmol/L) for all women. The median (first-third quartile) change in plasma folate concentration from baseline when women in both treatment groups were pooled for statistical analysis was 11.7 nmol/L (2.5-26.5 nmol/L) in pregnant women and 11.4 nmol/L (0.5-24.6 nmol/L) in nonpregnant women. The prevalence of inadequate folate status (,10 nmol/L) decreased in both groups from 8.8% to 7.5% (P = 0.71) among pregnant women and from 16.3% to 7.8% (P = 0.03) among nonpregnant women. Self-reported adherence was significantly associated with change in plasma folate concentrations from baseline among nonpregnant women (P , 0.0001) but not among pregnant women (P = 0.20), regardless of whether the pregnant women initiated supplementation before or after conception (P = 0.18). Each 1% increase in overall percentage adherence was associated with a 0.42-nmol/L improvement in change in plasma folate from baseline (P , 0.0001) among nonpregnant women compared with only a 0.14-nmol/L improvement in change in plasma folate from baseline (P = 0.20) among pregnant women.
DISCUSSION
The design of the current study was unique in 2 ways: the intervention (IFA or FA) commenced before or very early in the first trimester of pregnancy rather than later during pregnancy, and the supplement was provided as a powder added to food rather than a more traditional tablet or capsule. Among pregnant women in the current study, periconceptional IFA supplementation compared with FA supplementation did not significantly decrease anemia at 15 wk of gestation. Results indicate that at least a moderate level of adherence to iron supplementation well before conception is necessary to prevent anemia during early pregnancy. Among nonpregnant women, 9 mo iron supplementation significantly decreased anemia and improved iron stores.
Our final sample size of .30 women per treatment group provided us with 80% power to detect a difference of 8 g/L (611 g/L) in hemoglobin concentration at a 0.05 significance level (18) . Our study showed that the actual difference in hemoglobin concentration between the treatment groups was much smaller (mean: 1.00 g/L; 95% CI: 24.1, 6.1) and had a larger degree of individual variability. Whereas a larger sample size would have been needed to detect a statistically significant difference, results of our study found no clinically significant change in maternal hemoglobin among pregnant women despite iron supplementation.
A possible explanation for why maternal hemoglobin and iron stores were not significantly affected by IFA supplementation in pregnant women is that iron status was already fairly good at baseline. Among pregnant women, the mean (6SD) ferritin concentration at baseline was 54.9 6 38.5, and 6% of these women were iron deficient (ferritin ,12 lg/L). It has been suggested that the placenta and fetus may be able to compete effectively for iron among mothers with good iron status (29) . A study in the United States found that iron supplementation initiated in early pregnancy to initially iron-replete women did not improve maternal iron status and yet led to a surprisingly large increase in mean (6SD) birth weight (206 6 565 g; P = 0.01) among infants whose mothers received iron compared with a placebo (9) . As stated by Rasmussen and Stotlzfus (29), those results (9) may have been interpreted as spurious had it not been for a much larger randomized controlled trial in Nepal that found that iron supplementation in early pregnancy to women with initially poor nutritional status increased mean birth weight by 37 g (95% CI, 216, 90) compared with control (7). A distinguishing feature of both of those studies (7, 9) and the present study is that iron supplementation started earlier in pregnancy as compared with previous iron supplementation trials that have been recently reviewed (4, 30) . Unfortunately, the current study was not powered to detect differences in infant birth weight; therefore, we were unable to determine whether periconceptional iron supplementation led to significantly heavier infants compared with a control group. On the basis of calculations by Rasmussen (4), we would have needed 250 women per treatment group to detect a 100-g difference in birth weight. The effect of periconceptional iron supplementation on functional outcomes in both the mother and infant is an important area of future research and would benefit from investigation of the biological pathways by which maternal iron status affects fetal metabolism and growth (29) . It is also possible that IFA supplementation had no effect among pregnant women because of low adherence (57.7% 6 26.9%) and a relatively short period of supplementation. Pregnant women were in the study for an average of 136.3 6 36.6 fewer days and therefore consumed the contents of 94.5 6 54.5 fewer sachets compared with nonpregnant women. On the assumption that plasma folate concentrations would reflect adherence, we attempted to verify self-reported adherence by examining the association between adherence and plasma folate concentrations. We found that the association was statistically significant among nonpregnant but not pregnant women. Pregnant women may have reported their adherence inaccurately or were at different stages of hemodilution at the time of blood sampling, which affected the relation between self-reported intake and plasma folate concentration.
The level of adherence in the current study was similar to percentage adherence (61%) reported in a study in Bangladesh that used a pill bottle with an electronic counting device to compare the effectiveness of a daily versus weekly regimen of iron supplementation during pregnancy (31) . However, adherence among pregnant women in this study (57.7%) was much 1 Values are medians or percentages, where indicated; ranges (first-third quartiles) in parentheses. FA, folic acid; IFA, iron and folic acid. Multivariate linear regression analyses were performed for change in hematologic indexes controlled for treatment group and literacy (n = 116).
2 Defined as hemoglobin ,120 g/L.
FIGURE 2. Change in hemoglobin concentrations (g/L) from baseline by overall percentage adherence among pregnant women who initiated supplementation before pregnancy or in early pregnancy. Values on the x axis represent quartiles for overall percentage adherence (minimum, first, second, third, and maximum). Error bars represent upper and lower 95% CIs for adjusted mean estimates of the change in hemoglobin from baseline performed by using multivariate analysis (n = 88). To clearly see the size of the error bars, upper error bars are shown for women supplemented before pregnancy and lower error bars are shown for women supplemented in early pregnancy. P values for timing of supplementation and overall percentage adherence are adjusted for treatment group, literacy, and gestational age.
lower than in Nepal (86-88%), where fieldworkers also conducted monthly house-to-house visits to deliver and monitor iron supplements (7) . One possible reason is the timing of supplementation. In the Nepal study, supplementation commenced after a woman knew she was pregnant. It is possible that women in our study were less compliant because they perceived less benefit from supplement use before pregnancy. In a subsequent article, investigators of the Nepal study found that adherence was greater among women who were older and who had more children, possibly due to more exposure to antenatal messages (32) . Woman in our study may have been less adherent than women in the Nepal study because they were nulliparous and considerably younger (50% were adolescents).
The current study is the first trial to examine the effect of periconceptional supplementation by using a powdered micronutrient supplement. Recently, a study was conducted to determine the efficacy of 60 mg elemental iron and 400 lg folic acid delivered as a powdered micronutrient supplement compared with tablets among pregnant women in rural Bangladesh (15) . At 32 wk, mean (6SD) hemoglobin was significantly higher among women who consumed the tablet (110.2 6 11.1 g/L) than in those who consumed the powdered supplement (105.6 6 11.1 g/L) (P , 0.05). Mean percentage adherence was higher in the tablet group than in the powdered supplement group (76% compared with 58%; P , 0.05). After adherence was controlled for, hemoglobin response did not differ between the groups. The study also found that the powdered supplement was commonly mixed with rice, curry, banana, and dry biscuits with a small amount of water (15) . In the present study, both treatment groups received supplements in the form of a powdered micronutrient supplement, and we did not collect information on acceptability or on how women consumed the contents of the sachets. However, because our study was conducted in the same geographical region as the previous study, it is likely that the 2 study populations share similar food habits and practices. Reduced iron absorption from the powdered mixture may have occurred because of high amounts of phytate in rice or from mixing the powdered micronutrients with liquids, causing some of the particles to be lost in the process because of sticking to a glass or bowl. Although women in Bangladesh traditionally consume their meal after their husband and children have been fed, it is uncertain whether adding a powdered form of micronutrients to their food was difficult in household or social situations in which food is shared. Further studies on adherence in this age group need to examine preferences for modality of supplements in relation to socioeconomic and cultural factors.
In conclusion, results show that 9 mo of daily IFA supplied as a powder supplement to nonpregnant women in rural Bangladesh decreases anemia and increases iron stores. We did not find a positive effect among pregnant women. Before large-scale periconceptional IFA supplementation programs are implemented, there is a need for effectiveness studies and research that examines the effect of periconceptional IFA supplementation on maternal and infant outcomes. The current study examined plasma folate, which is an indication of recent folate intake (33) , as a subsidiary outcome. Future studies would benefit from determining red blood cell folate concentrations, which are longterm indicators of folate status and can be related to reduction in risk of neural tube defects (27, 34) . The present study was a small-scale research trial with sufficient support to theoretically ensure that the IFA supplements were distributed and consumed, and yet adherence was only moderate. It has yet to be determined whether periconceptional IFA supplementation is a cost-effective strategy for preventing and controlling anemia during pregnancy and whether it can be effectively implemented at the operational level.
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